 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...487488489490491492493494495496497...507508» |
- | Rituxan (rituximab) / Roche
Trial completion, Metastases: Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 12, 2014
P2, N=106, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- Trial primary completion date: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma (clinicaltrials.gov) - May 12, 2014
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2016
- |||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial primary completion date: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - May 11, 2014
P3, N=900, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2014 --> Mar 2016 Trial primary completion date: Mar 2017 --> Jul 2016
- ||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial completion date: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - May 11, 2014
P3, N=900, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2017 --> Jul 2016 Trial completion date: Mar 2017 --> Jul 2016
- || Trial primary completion date: AHOD03P1: Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease (clinicaltrials.gov) - May 11, 2014
P=N/A, N=188, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Mar 2017 --> Jul 2016 Trial primary completion date: Sep 2013 --> Nov 2012
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia (clinicaltrials.gov) - May 5, 2014
P1/2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2013 --> Nov 2012 Trial primary completion date: Oct 2015 --> Oct 2016
- Trial primary completion date: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients (clinicaltrials.gov) - May 5, 2014
P2, N=104, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Nov 2014 --> Nov 2015
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=400, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia (clinicaltrials.gov) - May 5, 2014
P1/2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2014 --> Nov 2015 Recruiting --> Active, not recruiting
- Genasense (oblimersen) / Genta
Enrollment change, Combination therapy, IO biomarker, Metastases: Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - May 5, 2014
P1/2, N=69, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=31 --> 69
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
New P2 trial, Metastases: LMS02: Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma (clinicaltrials.gov) - May 4, 2014
P2, N=110, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- metformin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial primary completion date, Combination therapy: Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - May 1, 2014
P1, N=18, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=31 --> 69 Trial primary completion date: Jul 2014 --> Jul 2015
- metformin / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Trial completion date, Combination therapy: Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - May 1, 2014
P1, N=18, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Jul 2014 --> Jul 2015 Trial completion date: Jul 2014 --> Jul 2015
- obatoclax (GX 15-070) / Teva
Enrollment change, Combination therapy: Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (clinicaltrials.gov) - Apr 29, 2014
P1, N=22, Terminated, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jul 2014 --> Jul 2015 N=52 --> 22
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (clinicaltrials.gov) - Apr 28, 2014
P2, N=45, Active, not recruiting, Sponsor: University of Arkansas
- thioguanine / Generic mfg.
Enrollment open: Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 28, 2014
P2, N=125, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=52 --> 22 Active, not recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment change, Metastases: Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 27, 2014
P2, N=70, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting N=106 --> 70
- Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial initiation date, Post-transplantation: PTLD-2: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (clinicaltrials.gov) - Apr 24, 2014
P2, N=90, Not yet recruiting, Sponsor: Diako Ev. Diakonie-Krankenhaus gemeinn
N=106 --> 70 Initiation date: Apr 2014 --> Oct 2014
- || doxorubicin hydrochloride / Generic mfg.
New P3 trial: Adjuvant Radiotherapy Comparing TACE for Curative HCC (clinicaltrials.gov) - Apr 24, 2014
P3, N=150, Not yet recruiting, Sponsor: Guangxi Medical University
- || Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P3 trial, Combination therapy: Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ (clinicaltrials.gov) - Apr 22, 2014
P3, N=250, Not yet recruiting, Sponsor: The Lymphoma Academic Research Organisation
- | topotecan / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma (clinicaltrials.gov) - Apr 15, 2014
P1, N=31, Completed, Sponsor: Children's Oncology Group
Initiation date: Apr 2014 --> Oct 2014 No longer recruiting --> Completed
- sirolimus / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=7, Completed, Sponsor: Thomas Jefferson University
No longer recruiting --> Completed Trial completion date: Jan 2014 --> Apr 2013
- | Trial completion: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=7, Completed, Sponsor: Thomas Jefferson University
Trial completion date: Jan 2014 --> Apr 2013 Active, not recruiting --> Completed
- || olanzapine / Generic mfg.
New P3 trial, CINV: Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P3, N=372, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- Neulasta (pegfilgrastim) / Roche
Trial completion date: Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma (clinicaltrials.gov) - Apr 14, 2014
P2, N=39, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Trial completion date: Dec 2013 --> Jun 2014
- | doxorubicin hydrochloride / Generic mfg.
New P2 trial: Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer (clinicaltrials.gov) - Apr 14, 2014
P2, N=80, Completed, Sponsor: Panagen, Limited Liability Company
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
New P3 trial: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 10, 2014
P3, N=1400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Hepacid (pegargiminase) / Polaris Pharma
Enrollment open, Metastases: Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Apr 8, 2014
P1, N=36, Recruiting, Sponsor: Polaris Group
Trial completion date: Dec 2013 --> Jun 2014 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms (clinicaltrials.gov) - Apr 7, 2014
P2, N=46, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2010 --> Apr 2012
- Avastin (bevacizumab) / Roche
Trial completion: Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms (clinicaltrials.gov) - Apr 7, 2014
P2, N=46, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: Feb 2010 --> Apr 2012 Suspended --> Completed
- | DCVAC/OvCa / Sotio
New P2 trial: Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma (clinicaltrials.gov) - Apr 6, 2014
P2, N=60, Recruiting, Sponsor: Sotio a.s.
- DCVAC/OvCa / Sotio
Enrollment open: Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma (clinicaltrials.gov) - Apr 6, 2014
P2, N=60, Recruiting, Sponsor: Sotio a.s.
Suspended --> Completed Not yet recruiting --> Recruiting
- |||||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche
Enrollment open, Metastases: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) (clinicaltrials.gov) - Mar 30, 2014
P3, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- doxorubicin hydrochloride / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Metastases: SoraDox: Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial (clinicaltrials.gov) - Mar 30, 2014
P2, N=170, Active, not recruiting, Sponsor: PD Dr. med. Matthias Dollinger
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- New P2 trial: SINTART2: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients (clinicaltrials.gov) - Mar 26, 2014
P2, N=25, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- New P2 trial, Surgery: SINTART 1: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients (clinicaltrials.gov) - Mar 26, 2014
P2, N=40, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- | simvastatin / Generic mfg.
New P2 trial: Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin (clinicaltrials.gov) - Mar 24, 2014
P2, N=90, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma (clinicaltrials.gov) - Mar 23, 2014
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 18, 2014
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=30 --> 50
- peripheral blood stem cell transplantation / National Cancer Institute
Clinical: Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 18, 2014
P2, N=85, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 50 Recruiting --> Active, not recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment change: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 17, 2014
P3, N=1900, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=1580 --> 1900
- Rituxan (rituximab) / Roche
Trial initiation date: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 16, 2014
P2, N=61, Not yet recruiting, Sponsor: Fox Chase Cancer Center
N=1580 --> 1900 Initiation date: Mar 2014 --> Jul 2014
- ||||||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion, Surgery: EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Mar 16, 2014
P3, N=1164, Completed, Sponsor: Children's Oncology Group
Initiation date: Mar 2014 --> Jul 2014 Active, not recruiting --> Completed
- ||||||| Epogen (epoetin alfa) / Amgen, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: SWOG-CAN-NCIC-MA21: Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer (clinicaltrials.gov) - Mar 16, 2014
P3, N=2104, Completed, Sponsor: NCIC Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: NCI-2018-01851: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 13, 2014
P1, N=110, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Arzerra (ofatumumab) / Novartis, Genmab
Trial completion, Combination therapy: MUNIN: Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients (clinicaltrials.gov) - Mar 12, 2014
P2, N=59, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, Metastases: LABC: Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 8, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Barretos Cancer Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Enrollment closed, Combination therapy, Metastases: TH-CR-406: A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 5, 2014
P3, N=620, Active, not recruiting, Sponsor: Threshold Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Combination therapy: SELENE : A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 4, 2014
P3, N=400, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma (clinicaltrials.gov) - Mar 4, 2014
P=N/A, N=180, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Active, not recruiting